Revvity is a specialized life sciences and diagnostics platform with a diversified product suite and recurring revenue ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held ...

Revvity (NYSE:RVTY) executives said the company ended 2025 with results that exceeded internal expectations, helped by better-than-anticipated performance in diagnostics and improving trends in parts ...

Revvity Inc. (NYSE:RVTY) stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings. The Waltham, Massachusetts-based company reported first-quarter ...

Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Revvity (RVTY) announced it will host an investor day on Thursday, November 21 which will feature presentations by members of Revvity’s senior management team on the company’s key business initiatives ...

On Monday, Revvity Inc. (NYSE:RVTY) reported second-quarter sales of $691.69 million, down from $709.07 million, beating the consensus of $690.36 million. The life sciences and diagnostics company ...

Revvity, a company providing life science and diagnostics solutions, including automation and services for drug discovery and research, recently opened its new Scientific Center of Excellence in ...

Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world’s greatest health challenges Trusted partner to pharma, government and diagnostics customers with ...